THOMAS PINSON: Open Payments
NPI 1326021262 · SOUTHGATE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$920 in 47 payments from 18 companies in 2025. Trend: 2023 $1,605 · 2024 $894 · 2025 $920
Food & beverage: $920
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $231 |
| Otsuka America Pharmaceutical, Inc. | 6 | $142 |
| AstraZeneca Pharmaceuticals LP | 3 | $90 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $51 |
| Boston Scientific Corporation | 2 | $50 |
| GlaxoSmithKline, LLC. | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| IRONWOOD PHARMACEUTICALS, INC | 2 | $36 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| Ardelyx, Inc. | 2 | $29 |
Products named: VRAYLAR, REXULTI, AIRSUPRA, CAPLYTA, WATCHMAN FLX, TRELEGY ELLIPTA, MAVYRET, GVOKE HYPOPEN.
Industry payments across MI — which companies pay providers there.
